
Pricing Can’t Be Set in a Vacuum
As a follow-on to our blog, “Is Your Access Strategy Aligned?”, we now focus on one of the most critical—but often siloed—elements of BioPharma commercialization: Pricing. Many companies determine their new medicine’s price by doing a typical analog analysis whereby the price is anchored to the relative perceived value of the new medicine vs other […]